Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2019-03-04
Target enrollment:
Participant gender:
Summary
This is an open-label, three-cohort, phase Ib study to determine the safety, recommended
phase 2 dose (RP2D), and efficacy of Stereotactic Body Radiation Therapy (SBRT) in
combination with either (A) MEDI4736 alone, (B) tremelimumab alone, or (C) the combination of
MEDI4736 and tremelimumab for patients with unresectable locally advanced adenocarcinoma of
pancreas.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health